Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Registration is open for a leading conference on structural heart disease announced by the Cardiovascular Research Foundation, CRF.
News | Cardiovascular Business
Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit

April 5, 2024 — The Cardiovascular Research Foundation (CRF) has announced New York Valves: The Structural Heart Summit ...

Home April 05, 2024
Home
Cardiawave SA will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia
News | Cardiovascular Ultrasound
Cardiawave is Presenting the 30-day Follow-up Results from its “Valvosoft Pivotal Study” on the Teatment of Severe Symptomatic Aortic Valve Stenosis at ACC24

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

Home April 05, 2024
Home
Early coronary disease and impaired heart function, with increased coronary vessel wall thickness, in asymptomatic, middle-aged individuals living with HIV has been reported in a new study published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).
News | Population Health
New Study Finds Early Coronary Disease, Impaired Heart Function in Asymptomatic People with HIV

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

Home April 04, 2024
Home
Study shows women quickly catch up to men in terms of cardiovascular risk
News | Womens Cardiovascular Health
Heart Health Declines Rapidly After Menopause

April 2, 2024 — A woman’s cardiovascular risk can rise sharply after she goes through menopause, quickly catching up to ...

Home April 02, 2024
Home
Study finds patients on average consume more than twice the recommended daily amount of sodium with little variation across socioeconomic groups
News | Womens Cardiovascular Health
Majority of People with Heart Disease Consume Too Much Sodium

April 2, 2024 — Individuals with heart disease stand to gain the most from a low sodium diet but, on average, consume ...

Home April 02, 2024
Home
Large study adds to growing body of evidence that vaping may harm the heart
News | Heart Failure
Study Links E-Cigarette Use with Higher Risk of Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
Approvals based on positive CLEAR Outcomes data and reflect a highly differentiated product profile
News | FDA
U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new ...

Home April 01, 2024
Home
Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health and other institutions conclude that new technology could soon help doctors slash that number
News | Heart Valve Technology
New Technology Promises to Revolutionize Valvular Heart Disease Care

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
Analysis signals higher risk of hypertension among females resting less than seven hours compared with males, according to data to be presented at the upcoming American College of Cardiology Annual Scientific Session & Expo, ACC.24, to be held April 6-8 in Atlanta, GA.
News | Hypertension
Getting Too Little Sleep Linked to High Blood Pressure

April 1, 2024 — Sleeping fewer than seven hours is associated with a higher risk of developing high blood pressure over ...

Home April 01, 2024
Home
While likelihood of cardiomyopathy grows over time, the overall risk remains low
News | Pediatric Cardiology
ADHD Stimulants May Increase Risk of Heart Damage in Young Adults

March 29, 2024 — Young adults who were prescribed stimulant medications for attention-deficit/hyperactivity disorder (AD ...

Home March 29, 2024
Home
V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at ACC24
News | Heart Failure
V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
Findings from the admIRE study – freedom from atrial arrhythmia recurrence at 12 months – support the submission of the VARIPULSE Platform among U.S. patients
News | Atrial Fibrillation
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone
News | FDA
FDA Approves Merck’s WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension

March 27, 2024 — Merck, known as MSD outside of the United States and Canada, announced  that the U.S. Food and Drug ...

Home March 27, 2024
Home
Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at ACC24
News | Cardiovascular Clinical Studies
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be Presented at ACC.24

March 26, 2024 — Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL ...

Home March 26, 2024
Home
Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.
News | ACC
Bristol Myers Squibb to Present Data on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24

March 26, 2024 — Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II ...

Home March 26, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now